Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4329/wjr.v8.i5.449 http://scihub22266oqcxt.onion/10.4329/wjr.v8.i5.449 C4882402!4882402!27247711     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27247711.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       World+J+Radiol 2016 ; 8 (5): 449-59 Nephropedia Template TP {{tp|p=27247711|t=2016. Current status of transarterial radioembolization |pdf=|usr=}}{{27247711}} gab.com Text Current status of transarterial radioembolization JO: World J Radiol http://www.kidney.de/pget.php?&tw=1&pmid=27247711 #FOAvip Unresectable primary and secondary liver malignancies present a major problem in the treatment of solid tumors. Transarterial radioembolization (TARE) is an increasingly used technique for treating various types of malignant liver tumors. This approach is appealing, as the mechanism of action is independent from other loco-regional treatments and potentially complementary to systemic therapies. There are two commercially available products in use for TARE: 90Y-resin and 90Y-glass microspheres. Currently available data indicates TARE so be safe and effective in hepatocellular carcinoma (HCC) and metastatic liver disease. In HCC the results compare well with chemoembolization, while the role of TARE in combination with kinase inhibitors has yet to be established. Current data on TARE in metastatic liver disease is promising, but there is a strong need for prospective randomized trials comparing TARE and modern chemotherapeutic regimen to support the growing role of TARE in metastatic liver disease. Twit Text FOAVip Current status of transarterial radioembolization ????World J Radiol http://www.kidney.de/pget.php?&tw=1&pmid=27247711 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27247711 #FOAvip English Wikipedia <ref>{{Cite pmid|27247711}}</ref> Current status of transarterial radioembolization #MMPMID27247711 Mahnken AH World J Radiol 2016[May]; 8 (5): 449-59 PMID27247711show ga Unresectable primary and secondary liver malignancies present a major problem in the treatment of solid tumors. Transarterial radioembolization (TARE) is an increasingly used technique for treating various types of malignant liver tumors. This approach is appealing, as the mechanism of action is independent from other loco-regional treatments and potentially complementary to systemic therapies. There are two commercially available products in use for TARE: 90Y-resin and 90Y-glass microspheres. Currently available data indicates TARE so be safe and effective in hepatocellular carcinoma (HCC) and metastatic liver disease. In HCC the results compare well with chemoembolization, while the role of TARE in combination with kinase inhibitors has yet to be established. Current data on TARE in metastatic liver disease is promising, but there is a strong need for prospective randomized trials comparing TARE and modern chemotherapeutic regimen to support the growing role of TARE in metastatic liver disease. äCurrent status of transarterial radioembolization (epmc).pdf DeepDyve Pubget Overpricing